Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Neumología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
INTERVENTIONAL
Inicio: 13 de dic de 2011
ID: NCT01450761
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
INTERVENTIONAL
Inicio: 23 de sept de 2024
ID: NCT06497556
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
INTERVENTIONAL
Inicio: 29 de dic de 2022
ID: NCT05595642
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP)
INTERVENTIONAL
Inicio: 2 de dic de 2020
ID: NCT04678856
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
INTERVENTIONAL
Inicio: 19 de abr de 2019
ID: NCT03596866
Completado
Fase 3
ClinicalTrials.gov
A 24 Month, Multicenter, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients
INTERVENTIONAL
Inicio: 1 de ene de 2008
ID: NCT00622869
Terminado
Fase 3
ClinicalTrials.gov
A 52-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI add-on to Maintenance Triple Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
INTERVENTIONAL
Inicio: 14 de jul de 2021
ID: NCT04636801
Completado
Fase 3
ClinicalTrials.gov
A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease
INTERVENTIONAL
Inicio: 1 de jun de 2009
ID: NCT00929110
Terminado
Fase 2
ClinicalTrials.gov
A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer
INTERVENTIONAL
Inicio: 19 de nov de 2020
ID: NCT04581824
Completado
Fase 2
ClinicalTrials.gov
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
INTERVENTIONAL
Inicio: 1 de jun de 2008
ID: NCT00633789
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
INTERVENTIONAL
Inicio: 25 de feb de 2025
ID: NCT06646276
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
INTERVENTIONAL
Inicio: 16 de jul de 2018
ID: NCT03546907
Completado
Fase 2
ClinicalTrials.gov
A Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years With Asthma on a Background of Inhaled Corticosteroid Therapy
INTERVENTIONAL
Inicio: 1 de abr de 2012
ID: NCT01573767
Reclutando
Fase 3
ClinicalTrials.gov
AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)
INTERVENTIONAL
Inicio: 23 de jul de 2025
ID: NCT06758401
Completado
Fase 3
ClinicalTrials.gov
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
INTERVENTIONAL
Inicio: 1 de oct de 2018
ID: NCT03631706
Completado
Fase 2
ClinicalTrials.gov
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Dose Ranging Study Evaluating the Efficacy and Safety of GW642444M Administered Once Daily Compared With Placebo for 28 Days in Adolescent and Adult Subjects With Persistent Asthma
INTERVENTIONAL
Inicio: 1 de dic de 2007
ID: NCT00600171
Desconocido
ClinicalTrials.gov
Adherence to Low Tidal Volume in the Transition to Spontaneous Ventilation Mode in Patients With Acute Respiratory Failure in ICUs in Latin America
OBSERVATIONAL
Inicio: 12 de jun de 2023
ID: NCT06042036
Completado
Fase 3
ClinicalTrials.gov
A Phase IIIb Multicenter, 52 Week Treatment, Randomized, Blinded, Double Dummy, Parallel Group Efficacy Study Comparing the Effect of Inhaled Indacaterol 150 µg o.d. vs Inhaled Tiotropium 18 µg o.d. on Lung Function, Rate of Exacerbations and Related Outcomes in Patients With COPD
INTERVENTIONAL
Inicio: 1 de mar de 2009
ID: NCT00845728
Terminado
Fase 3
ClinicalTrials.gov
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor
INTERVENTIONAL
Inicio: 23 de dic de 2022
ID: NCT05605093
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)
INTERVENTIONAL
Inicio: 22 de dic de 2025
ID: NCT07128199
Anterior
1
...
42
43
44
...
434
Siguiente
Filtros